Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles

References

• Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985;228:1049–55
   PubMed Web of Science ®Google Scholar
• Chaturvedi D, Goswami A, Saikia PP, et al. Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev 2010;39:435–54
   PubMed Web of Science ®Google Scholar
• Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett 1995;91:41–6
   PubMed Web of Science ®Google Scholar
• Beekman AC, Barentsen AR, Woerdenbag HJ. Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. J Nat Prod 1997;60:325–30
   PubMed Web of Science ®Google Scholar
• Ikuhiko N, Henry L, Narendra PS, et al. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 2008;354:28–33
   PubMed Web of Science ®Google Scholar
• Zhang SM, Chen H, Glenn SG. Heme synthesis increases artemisinin-induced radical formation and cytotoxicity that can be suppressed by superoxide scavengers. Chem Biol Interact 2010;186:30–5
   PubMed Web of Science ®Google Scholar
• Steve O, Byung JK, Narendra PS, et al. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 2009;274:33–9
   PubMed Web of Science ®Google Scholar
• Hamilton DH, Turcot I, Stintzi A, et al. Large cooperativity in the removal of iron from transferrin at physiological temperature and chloride ion concentration. J Biol Inorg Chem 2004;9:936–44
   PubMed Web of Science ®Google Scholar
• Qian ZM, Li H, Sun H, et al. Targeted drug delivery via the transferring receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561–87
   PubMed Web of Science ®Google Scholar
• Gomme PT, McCann KB, Bertolini J. Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 2005;10:267–73
   PubMed Web of Science ®Google Scholar
• Reizenste P. Iron, free radicals and cancer. Med Oncol Tumor Pharmacother 1991;8:229–33
   PubMedGoogle Scholar
• David S, Tiphanie P, Cindy L, et al. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett 2002;179:151–6
   PubMed Web of Science ®Google Scholar
• Tracy RD, Ezequiel B, José AR, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Bba – Gen Subjects 2012;1820:291–317
   PubMed Web of Science ®Google Scholar
• Li JL, Wang L, Liu XY, et al. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett 2009;274:319–26
   PubMed Web of Science ®Google Scholar
• Tracy RD, Tracie D, Jose AR, et al. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol 2006;121:144–58
   PubMed Web of Science ®Google Scholar
• Ruibin L, Ren’an W, Liang Z, et al. P-Glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 2010;4:1399–408
   PubMed Web of Science ®Google Scholar
• Huijuan Z, Chengqun C, Lin H, et al. Targeting and hyperthermia of doxorubicin by the delivery of single walled carbon nanotubes to EC-109 cells. J Drug Target 2013;21:312–19
   Web of Science ®Google Scholar
• Chengqun C, Huijuan Z, Lin H, et al. Single-walled carbon nanotubes mediated neovascularity targeted anti-tumor drug delivery system. J Pharm Pharmaceut Sci 2013;16:40–51
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang M, Zhang N. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. Int J Nanomedicine 2011;6:2641–52
   PubMed Web of Science ®Google Scholar
• Wang L, Shi J, Zhang H. Synergistic anticancer effect of RNAi and photothermal therapy mediated by functionalized single-walled carbon nanotubes. Biomaterials 2013;34:262–74
   PubMed Web of Science ®Google Scholar
• Zhou F, Wu S, Song S, et al. Antitumor immunologically modified carbon nanotubes for photothermal therapy. Biomaterials 2012;33:3235–42
   PubMed Web of Science ®Google Scholar
• Ravi S, Davide P, Lara L, et al. Tissue Biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. PNAS 2006;103:3357–62
   PubMed Web of Science ®Google Scholar
• Jiao Z, Juanping L, Yuhong N, et al. Affinity and fluorescent detection of surfactants/ssDNA and single-walled carbon nanotube. Trans Nonferrous Met Soc China 2013;23:456−61
   Web of Science ®Google Scholar
• Liu X, Tao H, Yang K, et al. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials 2011;32:144–51
   PubMed Web of Science ®Google Scholar
• Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005;9:674–9
   PubMed Web of Science ®Google Scholar
• Lu YJ, Wei KC, Ma CC, et al. Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces 2012;89:1–9
   PubMed Web of Science ®Google Scholar
• Fraser JR, Laurent TC. Turnover and metabolism of hyaluronan. Ciba Found Symp 1989;143:41–53
   PubMedGoogle Scholar
• Choi KY, Chung H, Min KH. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010;31:106–14
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun J, Cao W. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011;421:160–9
   PubMed Web of Science ®Google Scholar
• Toole BP, Wight TN, Tammi MI. Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 2002;277:4593–6
   PubMed Web of Science ®Google Scholar
• Brown TJ. The development of hyaluronan as a drug transporter and excipient for chemotherapeutic drugs. Curr Pharm Biotechnol 2008;9:253–60
   PubMed Web of Science ®Google Scholar
• Banerji S, Wright AJ, Noble M. Structures of the CD44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat Struct Mol Biol 2007;14:234–9
   PubMed Web of Science ®Google Scholar
• Yoon HY, Koo H, Choi KY. Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 2012;33:3980–9
   PubMed Web of Science ®Google Scholar
• Nel AE, Madler L, Velegol D. Understanding biophysicochemical interactions at the nano-bio interface. Nature Materials 2009;8:543–57
   PubMed Web of Science ®Google Scholar
• Shim M, Kam NW, Chen RJ. Functionalization of carbon nanotubes for biocompatibility and biomolecular recognition. Nano Lett 2002;2:285–8
   Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751–60
   PubMed Web of Science ®Google Scholar
• Song SS, Qi H, Xu JW, et al. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting. Pharm Res 2014;31:2988–3005
   PubMed Web of Science ®Google Scholar
• Gao LY, Liu XY, Chen CJ, et al. Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials 2014;35:2066–78
   PubMed Web of Science ®Google Scholar
• Michael BK, Jiri B. Cell-cycle checkpoints and cancer. Nature 2004;432:316–23
   PubMed Web of Science ®Google Scholar
• Gary KS, Manish AS. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;23:9408–21
   PubMed Web of Science ®Google Scholar
• Dewey WC, Hopwood LE, Sapareto SA. Cellular responses to combinations of hyperthermia and radiation. Radiology 1977;123:463–74
   PubMed Web of Science ®Google Scholar